Abstract
Mathematical modeling studies have shown that repetitive screening can be used to mitigate SARS-CoV-2 transmission in primary schools while keeping schools open. However, not much is known about how transmission progresses within schools and whether there is a risk of importation to households. In this study, we reconstructed outbreaks observed during a prospective study in a primary school and associated households in Liège (Belgium) during the academic year 2020-2021. In addition we performed a simulation study to investigate how the accuracy of estimated weekly positivity rates in a school depends on the proportion of a school that is sampled in a repetitive screening strategy. We found that transmission occurred mainly within the school environment and that observed positivity rates are a good approximation to the true positivity rate, especially in children. This study shows that it is worthwile to implement repetitive testing in school settings, which in addition to reducing infections can lead to a better understanding of the extent of transmission in schools during a pandemic and importation risk at the community level.
Competing Interest Statement
Ch.M. received grants from Fondation Léon Fredericq and FIRS during the conduct of the study. N.H. reports that the Universities of Antwerp and Hasselt obtained grants from several vaccine manufacturers for specific studies aimed at modeling the spread of infectious diseases outside the submitted work for which N.H. is the principal investigator. N.H. obtains no personal remuneration. All other authors declare no competing interests.
Funding Statement
The study was funded by Fondation Léon Fredericq and by the Liège University Hospital Research funds. P.J.K.L. gratefully acknowledges support from the Research Foundation Flanders (FWO) via postdoctoral fellowship 1242021N (P.J.K.L.). P.J.K.L. also acknowledges support from the Research council of the Vrije Universiteit Brussel (OZR-VUB) via grant number OZR3863BOF, and from the Flemish Government through the AI Research Program. G.D. is an FNRS postdoctoral clinical master specialist. P.L. acknowledges support by the European Research Council under the European Union's Horizon 2020 research and innovation programme (grant agreement number 725422 - ReservoirDOCS) and the Research Foundation -- Flanders (`Fonds voor Wetenschappelijk Onderzoek -- Vlaanderen', G066215N, G0D5117N and G0B9317N). N.H. and A.T. acknowledge funding from the European Union's Horizon 2020 research and innovation programme - project EpiPose (Grant agreement number 101003688). This project was supported by the VERDI project (101045989), funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them. The computational resources and services used in this work were provided by the VSC (Flemish Supercomputer Center), funded by the Research Foundation Flanders (FWO) and the Flemish Government department EWI.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the ethics committee of Liège University Hospital (number: 2020-241), the school directors, and the local authorities.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data and computer code used for these analyses will be made available upon publication of the manuscript.
